Taihao Biotech secures funding to commercialize disruptive microfluidic molecular diagnostics

Recently, Beijing Taihao Biotech announced the successful completion of a new funding round. This round was exclusively invested by the Linyi Linshu Industry Fund under the management of Shanda Capital. The proceeds are earmarked primarily to accelerate the regulatory registration process for the company's core product—a rapid microfluidic nucleic acid test kit for infectious diseases—and to initiate the construction of a modern production base.

Since its inception in 2021, Taihao Biotech has been committed to revolutionizing molecular diagnostics. By leveraging disruptive microfluidic technology, the company aims to transform complex, time-consuming nucleic acid tests into automated, rapid diagnostics with streamlined, "one-click" operation. Its proprietary TurboFlow product series is designed to deliver full "sample-to-result" automation, thereby significantly minimizing the dependency on specialized operators and controlled laboratory environments. These capabilities are poised to play a pivotal role in diverse fields including disease control, animal epidemic surveillance, and environmental safety monitoring.

The proceeds from this round will accelerate the execution of Taihao Biotech's commercialization strategy. The company plans to establish its Phase I reagent production base by 2026. This facility, spanning over 3,000 square meters, is designed with an annual production capacity of one million units of its chip-based tests.

"We are deeply grateful to the Linyi Linshu Emerging Industry Fund for its strong endorsement of our technology platform and growth potential," said Dr. Wang Lei, Founder and CEO of Taihao Biotech. "This investment not only validates our team's dedicated R&D efforts over the past three years but, more importantly, marks a pivotal transition from innovation to commercial-scale manufacturing. Our vision is to decentralize precise and efficient molecular diagnostics, moving them from central labs directly to point-of-care settings, including outpatient clinics and primary care facilities. We are committed to strategically allocating these funds to advance our regulatory submissions and expand production capacity, with the goal of expediting the delivery of accessible and reliable testing solutions to the market."